Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which ...

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel ...

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted ...

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Ad…

Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for ...
Cure Today

Basics of Squamous Cell Bladder Cancer

Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...
Cure Today

Key Skin Cancer Treatment Updates From 2025 and What is Still to Come

The C-POST trial showed a disease-free survival benefit with adjuvant Libtayo for high-risk cutaneous squamous cell carcinoma, potentially influencing future standard care. Immunotherapy remains the ...
ascopubs.org

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Impaired homologous ...
Nature

Management and Treatment of Penile Squamous Cell Carcinoma

Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that accounts for over 95% of penile cancers. Management centres on early detection, risk stratification, and a tailored ...

Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic ...

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, ...
ascopubs.org

Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic nasal cavity and paranasal sinus squamous-cell carcinoma: A ...

Real world utilization of comprehensive genomic profiling (CGP) in head and neck squamous cell carcinoma (SCCHN). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Medscape

Navigating Esophageal Squamous Cell Cancer From Diagnosis to Treatment

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...
Nature

Squamous Cell Carcinoma in Breast Oncology

Squamous cell carcinoma of the breast is an exceptionally rare and aggressive malignancy characterised by keratinising epithelial cells that normally do not reside within mammary tissue. Representing ...